DEA Opens Psilocybin Scheduling Review Following FDA Breakthrough Therapy Designations

The Drug Enforcement Administration initiated a formal scheduling review for psilocybin and psilocin in November 2024, responding to three FDA Breakthrough Therapy Designations granted to clinical programs developing psilocybin-assisted psychotherapy for treatment-resistant depression, major depressive disorder, and PTSD. Breakthrough Therapy Designation is an FDA program designed to expedite development and review of drugs for serious conditions. The designation for psilocybin programs signals that FDA has reviewed preliminary clinical evidence and found it "substantial improvement over available therapy." Under the Controlled Substances Act, FDA's scientific and medical evaluation is one factor DEA must consider in scheduling determinations. Current status: Psilocybin is Schedule I under the CSA — classified as having no accepted medical use and a high potential for abuse. The Breakthrough Therapy Designations create evidence that psilocybin has potential accepted medical use in at least three therapeutic contexts, directly challenging the Schedule I criteria. DEA's review will apply the 21 U.S.C. § 811 eight-factor analysis. The review is expected to take 12–24 months. A formal scheduling proposal, if initiated, would require a separate NPRM process. State-level psilocybin therapeutic programs in Oregon and Colorado operate under state law and are not affected by the federal review, but federal rescheduling would significantly expand the therapeutic psilocybin landscape.